Skip to main content
Bliss GVS Pharma Limited logo

Bliss GVS Pharma Limited — Investor Relations & Filings

Ticker · BLISSGVS ISIN · INE416D01022 LEI · 335800GXY3YCGGP7KJ45 BSE.NS Manufacturing
Open in API
Filings indexed 1,243 across all filing types
Latest filing 2024-01-16 Regulatory Filings
Country IN India
Listing BSE.NS BLISSGVS

About Bliss GVS Pharma Limited

https://blissgvs.com/

Bliss GVS Pharma Limited specializes in the development, manufacturing, and marketing of diverse pharmaceutical formulations. The company is a global leader in the production of suppositories and pessaries, maintaining an extensive portfolio within these specialized dosage forms. Its therapeutic focus includes anti-malarials, anti-fungals, anti-bacterials, anti-inflammatories, and gastrointestinal treatments. The organization operates state-of-the-art manufacturing facilities compliant with international quality standards, including WHO-GMP. With a strategic focus on emerging markets, the company distributes its range of prescription and over-the-counter products across Sub-Saharan Africa, Southeast Asia, and Latin America, leveraging a robust supply chain to provide accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (NSE and BSE) regarding the loss of a share certificate and the issuance of a duplicate share certificate. It references compliance with SEBI regulations and requests brokers not to deal with the lost certificate. The content is a regulatory notification about share certificate status, not a financial report, earnings release, or management discussion. It does not contain financial data or detailed report content. The document length is short (1931 characters), and it serves as an official regulatory announcement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-01-16 English
BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/01/2024 ,inter alia, to consider and approve the Unaudited Standalone ....
Regulatory Filings Classification · 95% confidence The document is a formal notification addressed to stock exchanges about an upcoming Board Meeting scheduled for January 23, 2024. The purpose of the meeting is to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2023. The document also mentions the closure of the trading window for insiders until 48 hours after the announcement of these financial results. The document is short (1929 characters) and serves as an announcement of a future event (Board Meeting) rather than containing any financial data or results itself. It does not contain the financial results or detailed report but only informs about the meeting where such results will be approved. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement related to the company's compliance with listing obligations and disclosure requirements, and does not fit into more specific categories like Interim Report or Earnings Release which would require actual financial data or results.
2024-01-16 English
Pursuant to Regulation 39(3) of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that our Registrar and Transfer ....
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (NSE and BSE) regarding the loss of a share certificate and the issuance of a duplicate share certificate. It references compliance with SEBI regulations and requests brokers not to deal with the lost certificate. The content is an announcement about a specific share certificate issue, not a financial report, management change, or other detailed filings. The document length is short (1931 characters), and it is an informational notice about share certificate status under regulatory requirements. This fits best under the category of Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other specific categories.
2024-01-16 English
ESOP/ESOS/ESPS
Share Issue/Capital Change Classification · 100% confidence The document is an official communication addressed to stock exchanges (NSE and BSE) regarding the allotment of shares under the company's Employee Stock Options Plan (ESOP) 2019. It details the number of shares allotted, the increase in issued share capital, regulatory references to SEBI regulations, and includes an annexure with specifics about the allotment. The content is focused on informing about a share allotment event, which is a capital change related to employee stock options. There is no financial performance data, audit information, or management discussion. The document is not a report but an announcement of a capital change event. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2024-01-12 English
We would like to inform you that, the ESOP Allotment Committee of the Company at its meeting held on November 10, 2023, has approved the allotment of 18,000 equity shares of face value ....
Share Issue/Capital Change Classification · 95% confidence The document is an official communication addressed to stock exchanges (NSE and BSE) regarding the allotment of shares under the company's Employee Stock Options Plan (ESOP) 2019. It details the number of shares allotted, the increase in issued share capital, regulatory references to SEBI regulations, and includes an annexure with specifics about the share issuance. The content focuses on the allotment of shares and compliance disclosures related to share-based employee benefits. There is no financial performance data, earnings information, or management discussion. It is not a report or presentation but a regulatory announcement about a capital change due to ESOP allotment. Therefore, the document fits the category of Share Issue/Capital Change (SHA). The document length (5690 characters) and detailed disclosure support this classification with high confidence.
2024-01-12 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (NSE and BSE) regarding the intimation of loss of a share certificate and the issuance of a duplicate share certificate. It references Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to share certificate management. The content is about a specific shareholder's lost share certificate and the procedural update to the exchanges. This is a regulatory announcement related to shareholding records and does not contain financial data, management discussion, voting results, or other report types. It is not a report or a financial filing but a regulatory notification to the stock exchanges. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-01-08 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.